Citadel Advisors
CMPX icon

Citadel Advisors’s Compass Therapeutics CMPX Stock Holding History

Citadel Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Buy
+74,200
New +$428K ﹤0.01% 9859
2025
Q2 		– Sell
-40,500
Closed -$77K – 12816
2025
Q1 		$77K Buy
+40,500
New +$108K ﹤0.01% 11807

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's CMPX Position: Q1 2026 in Review

Citadel Advisors increased its Compass Therapeutics (CMPX) stake by 583% in Q1 2026, buying an estimated $3.55M and bringing the position to 721,410 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4799.

Citadel Advisors first reported a position in CMPX in Q4 2021 and has held it in 10 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Citadel Advisors held 721,410 shares of Compass Therapeutics worth $3.82M as of Q1 2026.
  • Citadel Advisors bought 615,728 Compass Therapeutics shares in Q1 2026, an estimated $3.55M.
  • Compass Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4799 holding.
  • Citadel Advisors first reported a position in Compass Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.